lunes, 20 de octubre de 2025

Strengthening Postapproval Monitoring: FDA’s Draft Guidance on Cell & Gene Therapy Products October 19, 2025 By Charles D. Snow & Mark A. Tobolowsky —

https://www.thefdalawblog.com/2025/10/strengthening-postapproval-monitoring-fdas-draft-guidance-on-cell-gene-therapy-products/?utm_source=rss&utm_medium=rss&utm_campaign=strengthening-postapproval-monitoring-fdas-draft-guidance-on-cell-gene-therapy-products

No hay comentarios: